Following receipt of an approvable letter from the FDA, United Therapeutics Corp. said its orphan drug for pulmonary arterial hypertension should reach the market sometime in the next two months. (BioWorld Today)
The failure of Tracleer to meet primary endpoints in a Phase III trial of chronic heart failure patients could be a blessing in disguise for Switzerland-based Actelion Ltd. (BioWorld Today)
The failure of Tracleer to meet primary endpoints in a Phase III trial of chronic heart failure patients could be a blessing in disguise for Switzerland-based Actelion Ltd. (BioWorld Today)
WASHINGTON Based on President George Bush’s proposed budget for fiscal year 2003, it appears that biotechnology companies filing drug applications with the FDA will be paying a higher cost. (BioWorld Today)
WASHINGTON Based on President George Bush’s proposed budget for fiscal year 2003, it appears that biotechnology companies filing drug applications with the FDA will be paying a higher cost. (BioWorld Today)
Nastech Pharmaceutical Co. Inc. licensed its nasally administered apomorphine product for sexual dysfunction in both men and women to Peapack, N.J.-based Pharmacia Corp. in a deal with a $56.4 million potential. (BioWorld Today)
Nastech Pharmaceutical Co. Inc. licensed its nasally administered apomorphine product for sexual dysfunction in both men and women to Peapack, N.J.-based Pharmacia Corp. in a deal with a $56.4 million potential. (BioWorld Today)
